Loading...
Market
What will be the overall consumer satisfaction with FluMist nasal spray by the end of the 2024-2025 flu season?
2
Resolution / Starting Odds
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
Surveys and reviews from health organizations and consumer feedback platforms
Story
FDA Approves FluMist Nasal Spray, First Self-Administered Flu Vaccine
Sep 20, 2024, 08:01 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval, announced on Friday, marks the first time a self-administered flu vaccine can be administered without the need for a healthcare provider. FluMist is licensed for individuals aged 2 to 49 and will be available for at-home use starting next flu season. Patients will need to complete a screening and eligibility assessment through a third-party pharmacy before obtaining the vaccine. The FDA's decision is part of its broader effort to expand consumer access to medicines and reduce healthcare costs and barriers, providing an alternative to flu shots.
View original story
Similar markets
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Convenience • 25%
Cost • 25%
Fear of needles • 25%
Effectiveness • 25%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%